Speaker Series
The speaker series attracts top-tier participants to our research community to share their experiences and discuss relevant topics of interest to entrepreneurs. These speakers are chosen from a broad range of expertise. To date our program has invited private investors, company CEOs, professionals from the pharma and biotech sector and seasoned entrepreneurs. Informal receptions are organized after talks to encourage networking within our community.
CRG Entrepreneurship Week 2024
The CRG Entrepreneurship Week is an annual event that brings together budding entrepreneurs, industry leaders, and seasoned professionals to foster innovation and entrepreneurship. This year’s edition we will have talks by:
The sessions below are open to the CRG community only.
You can join the sessions by clicking on this link.
July 1, 2024
10:00 h
Miquel Vila-Perelló – CEO of SpliceBio
"The Scientist's Journey"
July 2, 2024
12:00 h
Marina Rigau – CEO of Mimark
"Meet the Entrepreneur"
July 3, 2024
12:00 h
Daniel Oliver – Partner at Capital Cell
"Meet the Investor"
July 4, 2024
11:00 h
Héctor Pérez- VP at Ability Pharma
"Into the Clinical Path"
CRG Entrepreneurship Week 2023
Once again, we celebrate the CRG Entrepreneurship Week, a time to meet and discuss with innovators and the entrepreneurship community, who dream big and inspire others to bring their ideas to life while driving socio-economic growth and welfare.
Targeting students, researchers, alumni, mentors, start-ups, industry, investors and other innovation partners.
The sessions below are open to the CRG community only.
You can join the sessions by clicking on this link.
April 24, 2023
10:30 h
Evan Floden, Seqera Labs
"The Scientist's Journey"
April 25, 2023
12:00 h
Joan Perelló, Sanifit
"Meet the Entrepreneur"
April 27, 2023
09:30 h
Malcolm Bain, Across Legal SLP
"Software Protection"
April 27, 2023
14:00 h
Gabor Heltovics, NLC Ventures
"Meet the Venture Builder"
TBDO Sessions Malcolm Bain
14/09/202212:00473.10TBDO SessionsMalcolm BainAcross LegalLicensing research software: options and challenges.Host: Sanz Molinero, Ana IsabelAbstract:Malcolm is an English solicitor and Spanish abogado. He has worked as an Information Technology and Intellectual Property lawyer over the last 20 years, with a specialisation in technology licensing, open source software and content, technology transfer and privacy.
In 2006, together with his partner Manuel Martínez, he founded his own firm “id-law partners” as a boutique specialized in IP and ICT. In May 2018, both incorporated this firm into Across Legal. In addition to his professional activity advising entrepreneurs, private companies, public administrations and open source projects, Malcolm is a member of the Free Software Foundation Europe and ASTP, associate professor of law at the University of Barcelona, ¿¿mentor in Tecniospring Industry and other programs for entrepreneurs and frequent speaker at conferences and seminars in the field of ICTs and entrepreneurship in the digital world.
TBDO Sessions Tony Kouzarides
28/02/202214:30OnlineTBDO SessionsTony KouzaridesSenior Group Leader, Gurdon Institute and Director/Co-founder of the Milner Therapeutics Institute"Lessons from a career in academia and business”Host: Sanz Molinero, Ana IsabelAbstract:Short Bio
Tony Kouzarides is professor of Cancer Biology at the University of Cambridge. He is a Senior Group Leader at the Gurdon Institute and director/co-founder of the Milner Therapeutics Institute. Tony did his PhD at the University of Cambridge and postdoctoral work at MRC Laboratory of Molecular Biology and at New York University Medical Center. His research group at the Gurdon Institute is focused on epigenetic modifications and their involvement in cancer. Tony is co-founder of Abcam plc, a research reagents supplier, based on the Cambridge Biomedical Campus, STORM Therapeutics, a drug discovery company based in on the Cambridge Babraham Campus, and Chroma Therapeutics, based in Oxford. He is the founder and director of Cambridge Gravity, an organization that supports Cambridge Science and the founder of a cancer charity in Spain (Vencer el Cancer). Tony is a Fellow of the Royal Society (FRS), a Fellow of the British Academy of Medical Sciences (FMedSci), a fellow of the American Academy of Arts and sciences (AAAS), a fellow of the Cyprus Academy of Science and a member of the European Molecular Biology organization. He has been awarded the Wellcome Trust Award for Research in Biochemistry Related to Medicine, the Tenovus Medal, the Bodossaki Foundation prize in Biology, the Bijvoet Medal, the Biochemical Society Award, the Novartis Medal and Prize, the Heinrich Wieland Prize, the Nemitsas Prize and the Cyprus Science Excellence award. Watch the seminar recording here: https://youtu.be/ehrfJBRYjyg
Cell therapy in regenerative medicine from an industrial focus
On initiative of the TBDO, Dr. Miguel Mulet will provide an overview of cell therapy in regenerative medicine from an industrial focus and how this field illustrates particularly well, the challenges and risks of the trip from science to product during PRBB-CRG Session of Friday April 29th 2016 from 12:00-13:00. In this overview, he will touch various aspects:
- Cell therapy as a pharmaceutical product.
- How Mechanism of Action has been a moving target in parallel with product development.
- The intellectual property challenge of protecting inventions involving cells.
- Adapting biologics regulation to cell therapy.
- The long path of clinical development.
- Moving from a laboratory craft to industrial manufacturing.
- Commercialization and Market Access.
Miguel Mulet is Director of Strategy and New Projects in TiGenix, which is a leading European cell therapy company. His primary role at TiGenix is focused on aligning the functions that drive the cell therapy pipeline in Crohn’s Disease and Acute Myocardial Infarct. In addition, and besides business development activities to broaden the current pipeline, he is in charge of advancing the market readiness of the current platforms through implementation of new technologies and process improvement initiatives.